Healthcare provider profile · identity verified

Susan I Fixman, MD

Internal Medicine · LAKEWOOD, CO · NPI 1184768970

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	705	211
Levothyroxine Sodium	Levothyroxine Sodium	459	136
Lisinopril	Lisinopril	427	135
Amlodipine Besylate	Amlodipine Besylate	303	92
Omeprazole	Omeprazole	284	98
Rosuvastatin Calcium	Rosuvastatin Calcium	284	92
Simvastatin	Simvastatin	279	87
Losartan Potassium	Losartan Potassium	270	88
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	249	31
Alendronate Sodium	Alendronate Sodium	248	80
Metformin Hcl	Metformin Hcl	186	60
Tramadol Hcl	Tramadol Hcl	185	30
Gabapentin	Gabapentin	153	40
Metoprolol Tartrate	Metoprolol Tartrate	151	47
Atenolol	Atenolol	138	40
Albuterol Sulfate Hfa	Albuterol Sulfate	133	74
Duloxetine Hcl	Duloxetine Hcl	125	40
Furosemide	Furosemide	112	41
Tamsulosin Hcl	Tamsulosin Hcl	112	40
Hydrochlorothiazide	Hydrochlorothiazide	111	32
Meloxicam	Meloxicam	111	37
Oxycodone Hcl	Oxycodone Hcl	107	17
Pantoprazole Sodium	Pantoprazole Sodium	105	32
Glipizide	Glipizide	98	30
Sertraline Hcl	Sertraline Hcl	98	33
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	97	28
Pradaxa	Dabigatran Etexilate Mesylate	93	34
Potassium Chloride	Potassium Chloride	91	35
Warfarin Sodium	Warfarin Sodium	91	33
Mirtazapine	Mirtazapine	84	33
Venlafaxine Hcl Er	Venlafaxine Hcl	82	22
Famotidine	Famotidine	81	25
Arexvy	Rsvpref3 Antigen/As01e/Pf	74	74
Trazodone Hcl	Trazodone Hcl	74	28
Fluticasone Propionate	Fluticasone Propionate	71	30
Metoprolol Succinate	Metoprolol Succinate	70	22
Allopurinol	Allopurinol	66	22
Alvesco	Ciclesonide	65	28
Fluoxetine Hcl	Fluoxetine Hcl	65	20
Metformin Hcl Er	Metformin Hcl	65	22
Citalopram Hbr	Citalopram Hydrobromide	57	15
Triamcinolone Acetonide	Triamcinolone Acetonide	56	32
Eliquis	Apixaban	55	14
Ezetimibe	Ezetimibe	55	17
Wixela Inhub	Fluticasone Propion/Salmeterol	55	22
Humulin N	Insulin Nph Human Isophane	51	20
Adacel Tdap	Diph,pertuss(Acell),tet Vac/Pf	47	47
Methocarbamol	Methocarbamol	43	suppressed
Shingrix	Varicella-Zoster Ge/As01b/Pf	43	41
Acyclovir	Acyclovir	42	16
Estradiol	Estradiol	42	16
Jardiance	Empagliflozin	41	12
Bupropion Xl	Bupropion Hcl	37	suppressed
Insulin Glargine-Yfgn	Insulin Glargine-Yfgn	37	17
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	37	12
Carvedilol	Carvedilol	35	18
Escitalopram Oxalate	Escitalopram Oxalate	35	suppressed
Prednisone	Prednisone	35	14
Finasteride	Finasteride	34	12
Lorazepam	Lorazepam	32	suppressed
Donepezil Hcl	Donepezil Hcl	31	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	29	suppressed
Spiriva Respimat	Tiotropium Bromide	29	12
Quetiapine Fumarate	Quetiapine Fumarate	28	suppressed
Nystatin	Nystatin	27	11
Trospium Chloride	Trospium Chloride	27	suppressed
Clopidogrel	Clopidogrel Bisulfate	24	suppressed
Pregabalin	Pregabalin	24	suppressed
Solifenacin Succinate	Solifenacin Succinate	24	suppressed
Alprazolam	Alprazolam	23	suppressed
Cefuroxime	Cefuroxime Axetil	23	18
Lovastatin	Lovastatin	23	suppressed
Pravastatin Sodium	Pravastatin Sodium	23	suppressed
Glimepiride	Glimepiride	21	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	20	suppressed
Propranolol Hcl	Propranolol Hcl	20	suppressed
Spironolactone	Spironolactone	20	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	20	suppressed
Azelastine Hcl	Azelastine Hcl	19	suppressed
Lidocaine	Lidocaine	19	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	19	suppressed
Fluconazole	Fluconazole	17	suppressed
Insulin Syringe	Syringe And Needle,insulin,1ml	17	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	17	suppressed
Verapamil Er	Verapamil Hcl	17	suppressed
Hydralazine Hcl	Hydralazine Hcl	16	suppressed
Tizanidine Hcl	Tizanidine Hcl	16	suppressed
Insulin Syringe	Syringe-Needle,insulin,0.5 Ml	15	suppressed
Methimazole	Methimazole	15	suppressed
Digoxin	Digoxin	14	suppressed
Erythromycin	Erythromycin Base	14	suppressed
Ibuprofen	Ibuprofen	14	suppressed
Ondansetron Odt	Ondansetron	14	suppressed
Diclofenac Sodium	Diclofenac Sodium	13	suppressed
Enoxaparin Sodium	Enoxaparin Sodium	13	suppressed
Nabumetone	Nabumetone	13	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	13	11
Sumatriptan Succinate	Sumatriptan Succinate	13	suppressed
Xarelto	Rivaroxaban	13	suppressed
Buspirone Hcl	Buspirone Hcl	12	suppressed
Cartia Xt	Diltiazem Hcl	12	suppressed
Celecoxib	Celecoxib	12	suppressed
Colchicine	Colchicine	12	suppressed
Humulin R	Insulin Regular, Human	12	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	12	suppressed
Ropinirole Hcl	Ropinirole Hcl	12	suppressed
Clobetasol Propionate	Clobetasol Propionate	11	suppressed
Diphenoxylate-Atropine	Diphenoxylate Hcl/Atropine	11	suppressed
Fenofibrate	Fenofibrate	11	suppressed
Montelukast Sodium	Montelukast Sodium	11	suppressed
Naloxone Hcl	Naloxone Hcl	11	suppressed
Phenytoin Sodium Extended	Phenytoin Sodium Extended	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error